Introduction

Primary gallbladder cancer (GBC) is a rare gastrointestinal malignancy but is the most common cancer arising in the biliary tract, representing 80–95% of all biliary tract cancers worldwide [1, 2]. Gallbladder cancer remains an aggressive cancer with an overall dismal outcome despite all the biomedical, technological, surgical, and chemotherapeutic advancements in the last decade. It is estimated that <5000 new cases are diagnosed each year in the US. Based on the available data, the incidence of GBC is 1–2 cases per 100,000 population in the US [2, 3]. Incidence steadily increases with age in both sexes, women are affected 2–6 times more often than men, and GBC is more common in non-Hispanic whites (NHW) than in African Americans (AA) [2, 4]. Several risk factors have been identified for GBC including gallstone disease, gallbladder polyps, chronic infection (Salmonella, Helicobacter), congenital biliary cyst, abnormal pancreaticobiliary duct junction, carcinogen exposure, obesity, and diabetes mellitus [5, 6].

Most of the GBC cases are found incidentally in patients undergoing either laparoscopic or open exploration for cholecystitis and/or cholecystitis. It is estimated that GBC can be found in 2% of cholecystectomies [7]. About 70% of cases of GBC are diagnosed at the regional or distant stage. Currently, the role of adjuvant radiation therapy in GBC treatment is not well established. Retrospective series have suggested some degree of benefit...
from adjuvant chemotherapy in the treatment of GBC but prospective trials have been limited by the lack of effective agents in this regard. However, even after complete resection, outcomes are poor, particularly for lesions penetrating through the serosa, invading liver or adjacent structures or node-positive disease. If GBC is resectable at the time of diagnosis, then resection is followed by adjuvant chemotherapy with or without radiation. For unresectable cases, chemotherapy is the modality of treatment [8, 9]. Observed survival rates from a series of 10,705 cases of GBC collected between 1989 and 1996 in the National Cancer Database and stratified according to stage at diagnosis using the newest American Joint Committee on Cancer (AJCC) criteria showed 50% and 2% survival at 5-years for stage I and IV, respectively [10]. Overall poor prognosis and survival associated with GBC is postulated to be related to an advanced stage at diagnosis, which is due both to the anatomic position of the gallbladder and the nonspecificity of symptoms [11]. With the introduction of laparoscopic cholecystectomy, greater numbers of cholecystectomies have been performed. It has been postulated that this change may have contributed to earlier incidental diagnosis of GBC in all stages with some improvement in overall survival [12].

Gallbladder cancer has been understudied. Only few studies have been published in the last decade on epidemiology and survival of GBC in the United States [13-15]. Most of the published studies focused on the surgical management of GBC and its associated survival [7-9, 16]. With all the recent improvement of GBC therapeutic modalities, there is a great need to explore the above mentioned factors at the population level. The goal of our study is to examine demographics and trends using a large population data source, Surveillance, Epidemiology and End Results (SEER) database, from 1973 to 2009, and to compare the treatment modalities of surgery and radiation on survival.

**Methods**

**Data source**

SEER, a program of National Cancer Institute (NCI) is a source of population-based cancer surveillance information in the US. SEER collects information on incidence, prevalence, and survival from specific geographic areas representing 28% of the total US population in 2010. The SEER Cancer Incidence Research Database consists of tumors reported to 18 registries since 2000, 13 registries since 1992, and nine registries since 1973. Geographic areas were selected for inclusion in the SEER program based on their ability to operate and maintain a high-quality population-based cancer reporting system and for their epidemiologically significant population subgroups. The population covered by SEER is comparable to the general US population with regard to measures of poverty and education. The SEER population tends to have a higher proportion of foreign-born persons than the general US population [17].

**Study population**

From 1973, SEER used the following broad racial categories: white, African American, American Indian/Alaska Native, Asian/Pacific Islander, and other. Hispanics were identified from the NAACCR Hispanic Identification Algorithm (NHIA) (Hispanics and non-Hispanics) variable. Our study population included patients diagnosed with GBC residing in SEER registries areas and reported in SEER database from 1973 to 2009 [17]. The analyses were performed according to major US race/ethnic groups—non-Hispanic whites (NHW), Hispanics (excluding those reported by the Alaska Native Registry), African Americans (AA), and Asians and Pacific Islanders (A/PI).

**Statistical analyses**

We used SEER*Stat and SAS software for the descriptive analyses [17, 18]. Joinpoint Regression Program was used to analyze trends in rates and distribution of stage. We calculated the overall and gender-specific incidence rate of GBC adjusted for age based on US Census Data 2000. We implemented trend analysis of GBC age-adjusted rates from 1973 to 2009 according to gender, and from 1992 to 2009 by race/ethnicity. Rates by race/ethnicity were limited to 1992–2009 due to the unavailability of a population file in the SEER database with detailed race/ethnicity for the years 1973–1991. We used SEER Historic Summary Stage data to generate trend analysis for stage at diagnosis from 1973 to 2009.

SAS was used to compare the distribution of GBC cases by descriptive variables across race/ethnicity groups [18]. We used Cox proportional hazard regression in SAS to calculate the adjusted relative hazard (RH) of GBC-related death. The survival analysis was performed with three endpoints: any cause of death, GBC-specific cause of death, and other cause of death. The last two endpoints are based on the variables SEER Cause-Specific Death Classification and SEER Other Cause of Death Classification.

The proportional hazard model’s main independent variables included whether the patient had surgery or radiation. Additional covariates included age in 5-year groups, year of diagnosis in 5-year periods, race in four groups, marital status, sex, histology in nine groups, stage
and grade. Missing values were assumed to be missing at random and those cases were simply dropped from the analysis. A two-tailed $P$ value of 0.05 or less was considered statistically significant.

**Results**

**Demographics**

A total of 18,124 incident cases of GBC were reported in SEER database from 1973 to 2009. It comprises about 1.4% of all gastrointestinal malignancies reported in the database during this time period. Table 1 shows the demographics of reported GBC in SEER database from 1973 to 2009. Gallbladder cancer is significantly ($P < 0.0001$) more common in females (71%) than males (29%). Most of the cases were reported in NHW (66%) followed by Hispanics (16%), while 9% of cases were reported in AA and 8% cases in A/PI. Compared to NHW (71%), more Hispanics females (78%) and less A/PI females (63%) were diagnosed with GBC ($P < 0.0001$).

**Incidence rate and trend**

The overall age-adjusted incidence rate of GBC for the study period of 1973–2009 is 1.4 per 100,000. It is higher in females than males (1.7 vs. 1.0 per 100,000; $P < 0.0001$). In the SEER-13 from 1992 to 2009, the rates are significantly higher for AA, A/PI, and Hispanics than NHW for both males and females. Moreover, the rate for females is higher than males across each of these four race/ethnic groups. Trend analysis showed that the incidence rates for both males and females have generally decreased significantly since 1973 (Fig. 1) as reported in SEER database with the rates for females having leveled-off since the mid-'90s.

**Stage at diagnosis and trend**

Trend analysis shows that the proportion of cases diagnosed at localized stage increased significantly since 1973, but appears to have stabilized since around the mid-'90s (Fig. 2). The proportion of cases diagnosed at regional stage has been generally decreasing since 1973 with a possible jump occurring in the mid to late 90s. Unfortunately, the proportion of distant stage cases has been increasing significantly since around the beginning of this century after a decreasing pattern since 1973. The distribution of stage was calculated for three time periods that roughly correspond to the two joint points seen in the proportion of localized and distant stage. The AAPC over 2000–2009 is significantly <0 for regional, significantly greater than zero for distant, and differs insignificantly from zero for localized. In the most recent time period 2000–2009, the percent of cases that are regional is significantly less than that of localized, and the percent of cases that are distant stage are significantly higher than that of localized. A/Pis and Hispanics have a higher proportion of cases diagnosed at the localized stage over 1973–2009 (Table 1).

**Survival analysis**

A total of 15,513 cases (86%) were selected for inclusion in survival analysis. Only patients who were diagnosed with GBC as their first reportable malignant primary tumor were included in survival analysis. Table 2 shows the variables that affected the relative hazard of death (RH).

### Table 1. Descriptive statistics of gallbladder cancer (GBC) in different race/ethnicities as reported in SEER database 1973–2009.

| All races | NHW (referent group) | AA | A/PI | Hispanic |
|-----------|---------------------|----|------|----------|
| N = 18,124 (100%) | N = 11,897 (66%) | N = 1547 (9%) | N = 1484 (8%) | N = 2899 (16%) |
| % male (95% CI) | 29 (28, 29) | 29 (28, 30) | 28 (27, 32) | 22* (20, 23) |
| % age <65 (95% CI) | 22 (21, 23) | 29 (28, 31) | 40* (37, 42) | 42* (40, 45) |
| % age 65–79 (95% CI) | 45 (44, 46) | 45 (44, 46) | 46 (44, 49) | 42* (40, 44) |
| % age 80+ (95% CI) | 28 (27, 29) | 32 (31, 33) | 23 (20, 26) | 18* (17, 19) |
| % diagnosed 2000–2009 | 50 (50, 51) | 46 (45, 47) | 63* (60, 65) | 62* (60, 64) |
| % married (95% CI) | 49 (48, 49) | 49 (48, 50) | 38* (36, 41) | 47* (45, 48) |
| % localized stage (95% CI) | 31 (30, 32) | 30 (29, 31) | 31 (29, 34) | 33* (31, 35) |
| % low grade (grade I and II) (95% CI) | 53 (52, 54) | 52 (51, 53) | 51 (48, 54) | 52 (50, 54) |
| % no surgery (95% CI) | 34 (33, 34) | 33 (33, 34) | 35 (33, 38) | 33 (31, 34) |
| % no radiation (95% CI) | 87 (86, 87) | 87 (86, 87) | 86 (84, 88) | 87 (86, 88) |

NHW, non-hispanic white, AA, African American, A/PI, Asian and Pacific Islander. 
*P < 0.05 in comparison to referent group.
of a GBC-related death as well as for any cause of death was significantly higher with older age, later stages, and higher grades at diagnosis. Survival is also better in females than males and in Asian/Pacific Islanders than other racial groups. The patients who did not receive any surgery had higher RHs for GBC-specific and any cause of death in comparison to patients who received surgery as either the only modality of treatment or in combination with radiation therapy. Among patients who did not receive radiation, not receiving surgery was also associated with a higher hazard of a non-GBC-specific cause of death. Similarly, not receiving radiation was associated with higher relative hazard for all three end-points. The highest survival was in patients who received both types of treatment (Table 2).

**Discussion**

Gallbladder cancer is an uncommon malignancy of the hepatobiliary tract. Currently GBC ranks fifth among gastrointestinal cancers. The global rates for GBC exhibit significant variability, reaching epidemic levels for some specific geographic regions and ethnicities. The basis for this wide variance most likely resides in differences in
environmental exposures, incidence, and prevalence of risk factors for GBC [2]. Nevertheless, its high fatality rate continues to pose a significant dismal outcome. With the changing risk exposure and stratification, specially increasing obesity, cholelithiasis, and increasing surgical interventions for many gallbladder diseases, the epidemiology and

| Variables | Any cause of death | GBC-specific cause of death | Other cause of death |
|-----------|--------------------|----------------------------|----------------------|
| No surgery/no radiation (95% CI) | 1.8* (1.7, 1.9) | 1.8* (1.7, 1.9) | 1.5* (1.3, 1.8) |
| No surgery/with radiation (95% CI) | 1.6* (1.4, 1.8) | 1.6* (1.4, 1.8) | 0.8 (0.5, 1.4) |
| Surgery | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| No radiation/no surgery (95% CI) | 1.6* (1.4, 1.8) | 1.5* (1.4, 1.7) | 2.9* (1.7, 4.9) |
| No radiation/with surgery (95% CI) | 1.4* (1.3, 1.5) | 1.4* (1.3, 1.5) | 1.6* (1.3, 1.9) |
| Radiation | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Age 10–34 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Age 35–39 (95% CI) | 1.4 (0.9, 2.0) | 1.3 (0.9, 2.0) | 1.4 (0.5, 3.8) |
| Age 40–44 (95% CI) | 1.6* (1.1, 2.3) | 1.5* (1.0, 2.2) | 1.4 (0.5, 3.7) |
| Age 45–49 (95% CI) | 1.8* (1.3, 2.6) | 1.7* (1.2, 2.5) | 1.9 (0.7, 4.8) |
| Age 50–54 (95% CI) | 1.9* (1.3, 2.6) | 1.8* (1.3, 2.6) | 1.4 (0.6, 3.6) |
| Age 55–59 (95% CI) | 1.9* (1.4, 2.7) | 1.8* (1.2, 2.5) | 2.2 (0.9, 5.4) |
| Age 60–64 (95% CI) | 2.3* (1.6, 3.1) | 2.0* (1.4, 2.9) | 2.9* (1.2, 7.1) |
| Age 65–69 (95% CI) | 2.4* (1.7, 3.3) | 2.1* (1.5, 3.0) | 3.4* (1.4, 8.4) |
| Age 70–74 (95% CI) | 2.6* (1.9, 3.6) | 2.2* (1.6, 3.2) | 4.4* (1.8, 10.8) |
| Age 75–79 (95% CI) | 3.2* (2.3, 4.4) | 2.7* (1.9, 3.9) | 5.3* (2.1, 12.8) |
| Age 80–84 (95% CI) | 3.5* (2.6, 4.9) | 2.9* (2.0, 4.1) | 8.0* (3.3, 19.4) |
| Age 85+ (95% CI) | 4.6* (3.3, 6.3) | 3.6* (2.5, 5.1) | 11.4* (4.7, 27.7) |
| Diagnosed 1973–1979 (95% CI) | 1.6* (1.5, 1.7) | 1.7* (1.6, 1.8) | 1.1 (0.9, 1.4) |
| Diagnosed 1980–1984 (95% CI) | 1.5* (1.4, 1.6) | 1.6* (1.4, 1.7) | 1.1 (0.9, 1.4) |
| Diagnosed 1985–1989 (95% CI) | 1.4* (1.3, 1.5) | 1.4* (1.3, 1.5) | 1.1 (0.9, 1.4) |
| Diagnosed 1990–1994 (95% CI) | 1.3* (1.2, 1.4) | 1.4* (1.3, 1.5) | 1.1 (0.9, 1.3) |
| Diagnosed 1995–1999 (95% CI) | 1.2* (1.1, 1.3) | 1.2* (1.1, 1.3) | 1.2 (1.0, 1.4) |
| Diagnosed 2000–2004 (95% CI) | 1.1* (1.1, 1.2) | 1.2* (1.1, 1.2) | 0.9 (0.8, 1.1) |
| Diagnosed 2005–2009 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Non-Hispanic White | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| African American (95% CI) | 1.1* (1.0, 1.2) | 1.0 (1.0, 1.1) | 1.4* (1.2, 1.7) |
| American Indian/Alaska Native (95% CI) | 1.2* (1.1, 1.4) | 1.2* (1.0, 1.4) | 1.3 (0.9, 1.9) |
| Asian or Pacific Islander (95% CI) | 0.9* (0.8, 0.9) | 0.8* (0.8, 0.9) | 0.9 (0.8, 1.1) |
| Not Hispanic | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Hispanic (95% CI) | 1.0 (0.9, 1.0) | 1.0 (0.9, 1.0) | 1.1 (1.0, 1.3) |
| Localized stage | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Regional stage (95% CI) | 2.4* (2.3, 2.5) | 2.9* (2.8, 3.1) | 1.2* (1.0, 1.3) |
| Distant stage (95% CI) | 3.8* (3.6, 4.0) | 4.8* (4.5, 5.1) | 1.2 (1.0, 1.4) |
| Well differentiated (grade I) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Moderately differentiated (grade II) (95% CI) | 1.2* (1.2, 1.3) | 1.3* (1.2, 1.5) | 1.0 (0.9, 1.2) |
| Poorly differentiated (grade III) (95% CI) | 1.7* (1.5, 1.8) | 1.8* (1.7, 2.0) | 1.2* (1.1, 1.4) |
| Undifferentiated, anaplastic (grade IV) (95% CI) | 1.7* (1.5, 2.0) | 1.9* (1.7, 2.2) | 1.1 (0.8, 1.6) |
| Married | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Separated or not married (95% CI) | 1.1* (1.0, 1.1) | 1.1* (1.0, 1.1) | 1.3* (1.2, 1.4) |
| Male (95% CI) | 1.1* (1.1, 1.2) | 1.1* (1.0, 1.1) | 1.5* (1.3, 1.6) |
| Female | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Unspecified neoplasms (95% CI) | 1.2* (1.1, 1.4) | 1.2* (1.0, 1.4) | 1.4* (1.0, 2.0) |
| Epithelial neoplasms, NOS (95% CI) | 1.0 (1.0, 1.1) | 1.0 (1.0, 1.1) | 1.0 (0.9, 1.3) |
| Squamous cell neoplasm (95% CI) | 1.2* (1.1, 1.4) | 1.2* (1.0, 1.4) | 1.2 (0.9, 1.7) |
| Adenomas and adenocarcinomas | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Cystic, mucinous, and serous neoplasm (95% CI) | 1.1* (1.1, 1.2) | 1.2* (1.1, 1.3) | 0.9 (0.7, 1.1) |
| Ductal neoplasm (95% CI) | 1.3 (0.9, 1.7) | 1.3 (0.9, 1.7) | 1.1 (0.4, 3.5) |
| Complex epithelial neoplasms (95% CI) | 1.4* (1.2, 1.5) | 1.4* (1.3, 1.6) | 0.9 (0.6, 1.3) |
| Complex mixed and stromal neoplasm (95% CI) | 1.1 (0.8, 1.5) | 1.3 (0.9, 1.8) | 0.2 (0.03, 1.3) |
| Other histologic groups (95% CI) | 1.1 (0.7, 1.7) | 0.9 (0.6, 1.5) | 2.7* (0.2, 6.1) |

*P < 0.05 in comparison to referent group.
survival of GBC is changing. Extended surgical resection, lymph node excision, or both may improve survival in certain patients with incidentally discovered gallbladder cancer [13, 14, 18]. To date, this study is the largest population-based study to evaluate the epidemiology, trend, and survival of GBC in the United States.

During the study period, incidence rate of GBC remained low in comparison to other gastrointestinal or hepatobiliary malignancies. The global historic data also suggest that it remained low in many other parts of the world [19]. The incidence rate has been decreasing over the last three decades for males. However, among females, the incidence rate had decreased from 1973 to the mid-’90s but has remained stable since then. During the study period, the proportion of localized stage GBC has increased until the mid-’90s; this shift may be explained by increased incidental findings of GBC at cholecystectomy, as well as improved treatment modalities for many gallbladder pathologies. This was noted among all races and it is reasonable to conclude that detection at early stages is a major contributor for increased GBC survival [20, 21]. However, our trend analysis reveals an alarming observation: there is a recent significant surge in the proportion of late stages at diagnosis since 2001 after a decline over long period of time since 1973. This alarming change in the trend deserves further evaluation and study. It is not documented in the available literature whether changes in risk factors or diagnostic modalities account for such increase in late-stage GBC.

Our study shows that survival of GBC is improving significantly over time. Survival is better in females than males and in A/PI than other groups. Patients who did not receive any surgery had higher RHs for GBC-specific and any cause of death in comparison to patients who received surgery as either the only modality of treatment or in combination with radiation. Among patients who did not receive radiation, not receiving surgery was also associated with a higher hazard of a non-GBC-specific cause of death. Similarly, not receiving radiation was associated with higher relative hazards for all three endpoints. The highest survival was in patients who received both types of treatment. The higher hazards for non-GBC-related death associated with no treatment suggests that patients who did not receive treatment were at a higher risk of death overall. The higher survival in patients who underwent treatment may reflect in part the higher expectation of survival in those patients compared to those who did not undergo treatment. The information provided by SEER, however, remains limited and does not allow for further assessment of various treatment modalities on survival. Randomized controlled trials are needed to further evaluate the effects of surgery and/or radiation on survival. Nevertheless, this study provides valuable contribution to the literature by conducting a powerful analysis of the variables impacting survival, including the observed beneficial effect of surgery and radiation, in large number of cases analyzed over approximately four decades. The beneficial survival impact of surgical approach on gallbladder cancer has been mixed. However, an aggressive surgical approach for patients with gallbladder cancer has been reported to substantially and significantly improve survival of gallbladder cancer patients [22]. In one study, the overall 5-year survival for patients with GBC who underwent curative resection was 21–69% [23]. In another study, 18% of patients received radiation therapy after curative intent surgery. The use of adjuvant radiation therapy was associated with a short-term survival benefit, but the benefit dissipated over time [24]. Although surgery is the mainstay of treatment for early or localized GBC, the study showed that few patients underwent aggressive surgery [25]. The common characteristic of these previously published studies have been their small number of surgical cases followed up and the observational nature of their design. Our study contributes to the previous studies with large number of cases and the ability to control for many intervening factors.

In this epidemiological study, we used the comprehensive and quality-controlled SEER database, which adds significant strength to our analysis. The SEER-18 registries which have reportable tumors from the year 2000 and later covered more than 28% of the total US population in 2010; cases linked to population data with the major race/ethnic categories are available back to 1992 for 13 of the registries; and data on tumors diagnosed back to 1973 are available for the SEER-9 registries with the major race/ethnic categories but with population race data only in the groups categorized as white, AA, and other. The population covered by SEER registries program is highly comparable to the general US population; however, it tends to be somewhat more urban than rural and has a higher proportion of foreign-born persons than the general US population [17]. Another limitation is SEER’s lack of information on comorbidities or access to health insurance for the period studied, which can be a confounder in the survival analysis. Further, SEER database lacks comprehensive analysis of the type and extent of surgery for the period studied.

In conclusion, GBC is rare cancer of the gastrointestinal tract, but its incidence has generally decreased over the past several decades and appears to have stabilized for females. We also document a trend change in the staging pattern of GBC revealing the proportion of cases diagnosed at distant stage increasing in recent years after a long period of decline since the 1970s. Along with these findings, we have revealed a significantly improved survival of GBC over time. Highest survival was associated with receiving both surgery and radiation.
Acknowledgments

None.

Conflict of Interest

None declared.

References

1. Lazcano-Ponce, E. C., J. F. Miquel, N. Muñoz, R. Herrero, C. Ferreccio, I. I. Wistuba, et al. 2001. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J. Clin. 51:349–364.
2. Hundal, R., and E. A. Shaffer. 2014. Gallbladder cancer: epidemiology and outcome. Clin. Epidemiol. 6:99–109.
3. Randi, G., M. Malvezzi, F. Levi, J. Ferlay, E. Negri, S. Franceschi, et al. 2009. Epidemiology of biliary tract cancers: an update. Ann. Oncol. 20:146–159.
4. Stinton, L. M., and E. A. Shaffer. 2012. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut. Liv. 6:172–187.
5. Strom, B. L., R. D. Soloway, J. L. Rios-Dalenz, H. A. Rodriguez-Martinez, S. L. West, J. L. Kinman, et al. 1995. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 78:1515–1517.
6. Randi, G., S. Franceschi, and C. La Vecchia. 2006. Gallbladder cancer worldwide: geographical distribution and risk factors. Int. J. Cancer 118:1591–1602.
7. Xu, X. Q., W. Liu, B. L. Li, T. Hong, C. J. Zheng, C. Wang, et al. 2013. Unsuspected gallbladder cancer during or after laparoscopic cholecystectomy. Chin. Med. Sci. J. 28:102–106.
8. Cho, S. Y., S. H. Kim, S.-J. Park, S. S. Han, Y. K. Kim, K. W. Lee, et al. 2010. Adjuvant chemoradiation therapy in gallbladder cancer. J. Surg. Oncol. 102:87–93.
9. Nakeeb, A., K. Q. Tran, M. J. Black, B. A. Erickson, P. S. Ritch, E. J. Quebbeman, et al. 2002. Improved survival in resected biliary malignancies. Surgery 132:555–563.
10. Edge, S. B., D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene, and A. Trotti. 2010. American joint committee on cancer staging manual, 7th ed, Springer, New York, NY. p. 211.
11. Eslick, G.D. 2010. Epidemiology of gallbladder cancer. Gastroenterol. Clin. North Am. 39:307–330.
12. Steinert, R., G. Nestler, E. Sagynaliev, J. Müller, H. Lippert, and M. A. Reymond. 2006. Laparoscopic cholecystectomy and gallbladder cancer. J. Surg. Oncol. 93:682–689.
13. Le, M. D., D. Henson, H. Young, and J. Albores-Saavedra. 2011. Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy? Ann. Hepatol. 10:306–314.
14. Alberts, S. R., J. J. Kelly, R. Ashokkumar, and A. P. Lanier. 2012. Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973–2007. Int. J. Circumpolar Health 71:17521.
15. Kiran, R. P., N. Pokala, and S. J. Dudrick. 2007. Incidence pattern and survival for gallbladder cancer over three decades—an analysis of 10301 patients. Ann. Surg. Oncol. 14:827–832.
16. Liu, G.-J., X.-H. Li, Y.-X. Chen, H.-D. Sun, G.-M. Zhao, and S.-Y. Hu. 2013. Radical lymph node dissection and assessment: impact on gallbladder cancer prognosis. World J. Gastroenterol. 19:5150–5158.
17. Surveillance, Epidemiology and End Results (SEER) Program. Available at http://seer.cancer.gov/ (accessed January 15, 2014).
18. SAS Institute Inc., Cary, NC. Available at http://www.sas.com/ (accessed 1 July 2015).
19. Wang, Y.C., L. J. Wei, J. T. Liu, S. X. Li, and Q. S. Wang. 2012. Comparison of cancer Incidence between China and the USA. Cancer Biol. Med. 9:128–132.
20. Panebianco, A., A. Volpi, C. Lozito, A. Prestera, P. Ialongo, and N. Palasciano. 2013. Incidental gallbladder carcinoma: our experience. G. Chir. 34:167–169.
21. Downing, S. R., K. A. Cadogan, G. Ortega, T. A. Oyetunji, S. M. Siram, and D. C. Chang. 2011. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: effect of extended surgical resection. Arch. Surg. 146:734–738.
22. Dixon, E., C. M. Jr Vollmer, A. Sahajpal, M. Cattral, D. Grant, C. Doig, et al. 2005. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann. Surg. 241:385–394.
23. Lai, C. H., and W. Y. Lau. 2008. Gallbladder cancer—a comprehensive review. Surgeon 6:101–110.
24. Hyder, O., R. M. Dodson, T. Sachs, M. Weiss, S. C. Mayo, M. A. Choti, et al. 2014. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched surveillance, epidemiology, and end results analysis. Surgery 155:85–93.
25. Coburn, N. G., S. P. Cleary, J. C. Tan, and C. H. Law. 2008. Surgery for gallbladder cancer: a population-based analysis. J. Am. Coll. Surg. 207:371–382.